Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III
NCT ID: NCT04918108
Last Updated: 2024-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2021-01-01
2021-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single-center Trial of Patients With Aortic Dissection in the Chinese XinJiang Province
NCT02378103
Blood Biomarker Discovery by Raman Spectroscopy in Acute Aortic Dissection
NCT05206032
Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection
NCT01860768
Clinical Characteristics and Prognosis of Aortic Dissection in China (CLASSIC)
NCT05999188
The Roles of Intraluminal Pressure and the Dilation of Tunica Media in the Development of Aortic Dissection
NCT03030521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
inflammatory subphenotype
inflammatory response
laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
inflammatory response
laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with hematological diseases, infectious diseases, malignant tumors, immune system diseases, or severe liver diseases.
* Preoperative use of mechanical ventilation, blood transfusion, renal replacement therapy, extracorporeal membrane oxygenation, or intra-aortic balloon pump during the current admission.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Beijing Anzhen Hospital
OTHER
The Affiliated Hospital of Qingdao University
OTHER
First Affiliated Hospital of Shantou University Medical College
OTHER
The First Affiliated Hospital of Guangzhou Medical University
OTHER
TEDA International Cardiovascular Hospital
OTHER
Xiamen Cardiovascular Hospital
UNKNOWN
Shanghai East Hospital Tongji University
UNKNOWN
Tianjin Chest Hospital, Tianjin Medical University
UNKNOWN
Nanjing First Hospital, Nanjing Medical University
OTHER
Xiangya Hospital of Central South University
OTHER
The First Affiliated Hospital of Bengbu Medical University
OTHER
Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Liu
Investigator of Nanjing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu H, Zhang YY, Ding XH, Qian SC, Sun MY, Hamzah AW, Gao YN, Shao YF, Li HY, Wang K, Ni BQ, Zhang HJ; Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Investigators. Proximal vs Extensive Repair in Acute Type A Aortic Dissection Surgery. Ann Thorac Surg. 2023 Aug;116(2):270-278. doi: 10.1016/j.athoracsur.2023.04.019. Epub 2023 Apr 25.
Liu H, Qian SC, Shao YF, Li HY, Zhang HJ; 5A Investigators. Prognostic Impact of Systemic Coagulation-Inflammation Index in Acute Type A Aortic Dissection Surgery. JACC Asia. 2022 Oct 4;2(6):763-776. doi: 10.1016/j.jacasi.2022.06.007. eCollection 2022 Nov.
Liu H, Qian SC, Han L, Dong ZQ, Shao YF, Li HY, Zhang W, Zhang HJ. Laboratory signatures differentiate the tolerance to hypothermic circulatory arrest in acute type A aortic dissection surgery. Interact Cardiovasc Thorac Surg. 2022 Nov 8;35(6):ivac267. doi: 10.1093/icvts/ivac267.
Liu H, Qian SC, Zhang YY, Wu Y, Hong L, Yang JN, Zhong JS, Wang YQ, Wu DK, Fan GL, Chen JQ, Zhang SQ, Peng XX, Shao YF, Li HY, Zhang HJ. A Novel Inflammation-Based Risk Score Predicts Mortality in Acute Type A Aortic Dissection Surgery: The Additive Anti-inflammatory Action for Aortopathy and Arteriopathy Score. Mayo Clin Proc Innov Qual Outcomes. 2022 Sep 25;6(6):497-510. doi: 10.1016/j.mayocpiqo.2022.08.005. eCollection 2022 Dec.
Liu H, Qian SC, Shao YF, Li HY; Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Investigators Group. Anti-Inflammatory Effect of Ulinastatin on the Association Between Inflammatory Phenotypes in Acute Type A Aortic Dissection. J Inflamm Res. 2022 Jun 27;15:3709-3718. doi: 10.2147/JIR.S369703. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5A Plan
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.